Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the U.K.
Alimera Sciences, Inc. (ALIM)
Last alimera sciences, inc. earnings: 4/29 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alimerasciences.com/investor-relations
Company Research
Source: GlobeNewswire
Positive consistent results spur move to cap study at 550 patientsEnrollment complete as of January 2017 ATLANTA, July 19, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has given final approval to reduce the size of its ILUVIEN Registry Safety Study (IRISS). A post-marketing study, IRISS was originally designed to follow 800 ILUVIEN patients over five years. However, consistently positive real-world safety data from IRISS and other post-marketing studies led Alimera to seek a smaller sample size. Alimera enrolled the 550th patient in January of this year, making the anticipated last patient, last visit date January 2020. "We are very pleased to receive final approval from MHRA to complete enrollment in IRISS as it stands today," said Dan Myers, CEO of
Show less
Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALIM alerts
High impacting Alimera Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
ALIM
News
- Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Alimera Sciences Reports First Quarter 2024 Results [Yahoo! Finance]Yahoo! Finance
- Alimera Sciences Reports First Quarter 2024 ResultsGlobeNewswire
- Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences [Yahoo! Finance]Yahoo! Finance
- Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress ConferencesGlobeNewswire
ALIM
Earnings
- 5/14/24 - Miss
ALIM
Sec Filings
- 5/16/24 - Form SC
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- ALIM's page on the SEC website